Abstract
Objectives: We investigated how the Inflation Reduction Act (IRA) Medicare Part D benefit redesign may reduce out-of-pocket (OOP) drug expenditures for Medicare beneficiaries with dementia. Methods Design Utilizing data from the Health and Retirement Study (HRS) linked with Medicare claims, we simulated post-redesign OOP drug spending by applying the 2025 prescription drug cost-sharing rules to each beneficiary's pre-redesign Part D medication utilization data for 2016, adjusting for inflation. Participants Our study population comprised HRS respondents aged 65 and older in 2016, enrolled in Medicare fee-for-service, with at least one Part D drug claim in 2016, and diagnosed with dementia between 2000 and 2016 (n=1,677). Main Measures We compared pre- and post-redesign annual OOP drug expenditures stratified by: 1) low-income subsidy (LIS) eligibility status; 2) household income among non-LIS beneficiaries; 3) comorbidity count, and 4) cognitive impairment severity.
Results: Post-redesign, we project average annual OOP drug expenditures among LIS beneficiaries with dementia to decrease from $56 to $25 - representing a $31, or 55% reduction. In contrast, among non-LIS beneficiaries, average OOP drug expenditures is projected to decrease from $772 to $576, a $196, or 25% reduction. We project the reduction in OOP drug expenditures to be greater among beneficiaries with 6-8 comorbidities (45%) than among beneficiaries with fewer comorbidities (21-26%).
Conclusions: The IRA Medicare Part D benefit redesign will reduce OOP drug spending for beneficiaries with dementia, resulting in potentially marked savings not only for low-income beneficiaries and beneficiaries with a high comorbidity burden, but also for higher-income beneficiaries.